Trinity Delta Lighthouse: Futura Medical
Trinity Delta view: Futura Medical has successfully transitioned into a commercial stage healthcare company that is now profitable and cash generative. The much-anticipated US launch by Haleon is imminent, and commercial success in the US would be transformational, ensuring Futura Medical’s sustainable and growing profitability. Continued launches by partners, coupled with ongoing learnings from real-world evidence that confirm Eroxon’s unique position and potential, all bode well for future Eroxon revenues. While these are challenging to forecast in the near-term given unpredictable launch dynamics (channel fill and stocking effects, timing of batch release) and limited disclosure from partners (including variable milestone elements and undisclosed deal terms in different regions), over time visibility should improve. The market for ED treatments is significant and Eroxon appears ideally placed to carve a sizeable niche for itself. Our current Futura Medical valuation is £371m, equivalent to 123p per share, with the US opportunity worth more than Europe and Other Regions combined.Futura Medical is engaged in the research and development of pharmaceutical drugs and medical devices and their commercial exploitation. Co. focuses on developing products primarily for the consumer healthcare market. Co.'s focus is on sexual healthcare and pain relief. DermaSys® is Co.'s transdermal technology platform, for the absorption of active molecules through the skin. DermaSys® includes MED2002, a topical gel for the treatment of erectile dysfunction; TPR100, a topical diclofenac pain relief gel; TIB200, a topical ibuprofen pain relief gel; and SPR300, a topical methyl salicylate pain relief gel.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.